Literature DB >> 34912026

CD28 costimulation promotes an antitumor CD8+ T cell response in myeloid antigen-presenting cell niches.

Jacques A Nunès1, Daniel Olive2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34912026      PMCID： PMC8803824          DOI： 10.1038/s41423-021-00818-1

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  8 in total

1.  In the absence of its cytosolic domain, the CD28 molecule still contributes to T cell activation.

Authors:  Stéphanie O Morin; Valentin Giroux; Cédric Favre; Yassina Bechah; Nathalie Auphan-Anezin; Romain Roncagalli; Jean-Louis Mège; Daniel Olive; Marie Malissen; Jacques A Nunès
Journal:  Cell Mol Life Sci       Date:  2015-03-01       Impact factor: 9.261

2.  Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.

Authors:  Alice O Kamphorst; Andreas Wieland; Tahseen Nasti; Shu Yang; Ruan Zhang; Daniel L Barber; Bogumila T Konieczny; Candace Z Daugherty; Lydia Koenig; Ke Yu; Gabriel L Sica; Arlene H Sharpe; Gordon J Freeman; Bruce R Blazar; Laurence A Turka; Taofeek K Owonikoko; Rathi N Pillai; Suresh S Ramalingam; Koichi Araki; Rafi Ahmed
Journal:  Science       Date:  2017-03-09       Impact factor: 47.728

3.  Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.

Authors:  Jaikumar Duraiswamy; Riccardo Turrini; Aspram Minasyan; David Barras; Isaac Crespo; Alizée J Grimm; Julia Casado; Raphael Genolet; Fabrizio Benedetti; Alexandre Wicky; Kalliopi Ioannidou; Wilson Castro; Christopher Neal; Amandine Moriot; Stéphanie Renaud-Tissot; Victor Anstett; Noémie Fahr; Janos L Tanyi; Monika A Eiva; Connor A Jacobson; Kathleen T Montone; Marie Christine Wulff Westergaard; Inge Marie Svane; Lana E Kandalaft; Mauro Delorenzi; Peter K Sorger; Anniina Färkkilä; Olivier Michielin; Vincent Zoete; Santiago J Carmona; Periklis G Foukas; Daniel J Powell; Sylvie Rusakiewicz; Marie-Agnès Doucey; Denarda Dangaj Laniti; George Coukos
Journal:  Cancer Cell       Date:  2021-11-04       Impact factor: 31.743

4.  An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.

Authors:  Caroline S Jansen; Nataliya Prokhnevska; Viraj A Master; Martin G Sanda; Jennifer W Carlisle; Mehmet Asim Bilen; Maria Cardenas; Scott Wilkinson; Ross Lake; Adam G Sowalsky; Rajesh M Valanparambil; William H Hudson; Donald McGuire; Kevin Melnick; Amir I Khan; Kyu Kim; Yun Min Chang; Alice Kim; Christopher P Filson; Mehrdad Alemozaffar; Adeboye O Osunkoya; Patrick Mullane; Carla Ellis; Rama Akondy; Se Jin Im; Alice O Kamphorst; Adriana Reyes; Yuan Liu; Haydn Kissick
Journal:  Nature       Date:  2019-12-11       Impact factor: 49.962

5.  Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).

Authors:  Kathleen N Moore; Michael Bookman; Jalid Sehouli; Austin Miller; Charles Anderson; Giovanni Scambia; Tashanna Myers; Cagatay Taskiran; Katina Robison; Johanna Mäenpää; Lyndsay Willmott; Nicoletta Colombo; Jessica Thomes-Pepin; Michalis Liontos; Michael A Gold; Yolanda Garcia; Sudarshan K Sharma; Christopher J Darus; Carol Aghajanian; Aikou Okamoto; Xiaohua Wu; Rustem Safin; Fan Wu; Luciana Molinero; Vidya Maiya; Victor K Khor; Yvonne G Lin; Sandro Pignata
Journal:  J Clin Oncol       Date:  2021-04-23       Impact factor: 50.717

6.  Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock.

Authors:  Gila Arad; Revital Levy; Iris Nasie; Dalia Hillman; Ziv Rotfogel; Uri Barash; Emmanuelle Supper; Tomer Shpilka; Adi Minis; Raymond Kaempfer
Journal:  PLoS Biol       Date:  2011-09-13       Impact factor: 8.029

7.  Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients.

Authors:  Iva Truxova; Lenka Kasikova; Michal Hensler; Petr Skapa; Jan Laco; Ladislav Pecen; Lucie Belicova; Ivan Praznovec; Michael J Halaska; Tomas Brtnicky; Eva Salkova; Lukas Rob; Roman Kodet; Jeremy Goc; Catherine Sautes-Fridman; Wolf Herman Fridman; Ales Ryska; Lorenzo Galluzzi; Radek Spisek; Jitka Fucikova
Journal:  J Immunother Cancer       Date:  2018-12-04       Impact factor: 13.751

8.  An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.

Authors:  Paula Voabil; Marjolein de Bruijn; Lisanne M Roelofsen; Sanne H Hendriks; Simone Brokamp; Marlous van den Braber; Annegien Broeks; Joyce Sanders; Petra Herzig; Alfred Zippelius; Christian U Blank; Koen J Hartemink; Kim Monkhorst; John B A G Haanen; Ton N Schumacher; Daniela S Thommen
Journal:  Nat Med       Date:  2021-07-08       Impact factor: 53.440
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.